Nash D T, Schonfeld G, Reeves R L, Black H, Weidler D J
Am J Cardiol. 1987 May 29;59(14):87G-90G. doi: 10.1016/0002-9149(87)90164-0.
The antihypertensive and lipid effects of doxazosin and atenolol were compared in a 10-week, double-blind, parallel, placebo-controlled study. The 129 adults enrolled had mild to moderate hypertension (average supine diastolic blood pressures for doxazosin, atenolol and placebo were 100.6, 101.0 and 99.7 mm Hg, respectively). Patients were randomly assigned to treatment with doxazosin, 1 to 16 mg daily, atenolol, 50 to 100 mg daily or placebo. Among 114 patients included in the efficacy analysis, standing blood pressure (systolic/diastolic) changed by -13/-11 mm Hg with doxazosin (n = 37), -12/-12 mm Hg with atenolol (n = 39) and +1/-1 mm Hg with placebo (n = 38). Mean reductions in blood pressure for doxazosin and atenolol were significantly greater than those for placebo (p less than 0.01), although no statistically significant differences between the active agents were noted. Serum lipid measurements were evaluable for 116 patients, and the 38 doxazosin-treated patients in this group experienced reductions in total cholesterol, total triglyceride and very low density lipoprotein cholesterol levels. Both doxazosin and atenolol demonstrated comparable acceptance profiles. Doxazosin is an effective hypotensive agent with beneficial effects on serum lipid levels.
在一项为期10周的双盲、平行、安慰剂对照研究中，比较了多沙唑嗪和阿替洛尔的降压及降脂效果。入选的129名成年人患有轻度至中度高血压（多沙唑嗪、阿替洛尔和安慰剂组的平均仰卧位舒张压分别为100.6、101.0和99.7毫米汞柱）。患者被随机分配接受多沙唑嗪治疗，每日1至16毫克；阿替洛尔治疗，每日50至100毫克；或安慰剂治疗。在纳入疗效分析的114名患者中，多沙唑嗪组（n = 37）的站立血压（收缩压/舒张压）变化为-13/-11毫米汞柱，阿替洛尔组（n = 39）为-12/-12毫米汞柱，安慰剂组（n = 38）为+1/-1毫米汞柱。多沙唑嗪和阿替洛尔的平均血压降低幅度显著大于安慰剂组（p小于0.01），尽管未观察到活性药物之间有统计学显著差异。116名患者的血脂测量结果可评估，该组中38名接受多沙唑嗪治疗的患者总胆固醇、总甘油三酯和极低密度脂蛋白胆固醇水平均有所降低。多沙唑嗪和阿替洛尔的接受程度相当。多沙唑嗪是一种有效的降压药物，对血脂水平有有益影响。
